Botulinum toxin in clinical practice

被引:273
|
作者
Jankovic, J
机构
[1] Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA
来源
关键词
D O I
10.1136/jnnp.2003.034702
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Botulinum toxin, the most potent biological toxin, has become a powerful therapeutic tool for a growing number of clinical applications. This review draws attention to new findings about the mechanism of action of botulinum toxin and briefly reviews some of its most frequent uses, focusing on evidence based data. Double blind, placebo controlled studies, as well as open label clinical trials, provide evidence that, when appropriate targets and doses are selected, botulinum toxin temporarily ameliorates disorders associated with excessive muscle contraction or autonomic dysfunction. When injected not more often than every three months, the risk of blocking antibodies is slight. Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications.
引用
收藏
页码:951 / 957
页数:7
相关论文
共 50 条
  • [31] BOTULINUM A TOXIN INJECTION - FAILURES IN CLINICAL-PRACTICE AND A BIOMECHANICAL SYSTEM FOR THE STUDY OF TOXIN-INDUCED PARALYSIS
    HOLDS, JB
    FOGG, SG
    ANDERSON, RL
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 1990, 6 (04): : 252 - 259
  • [32] Clinical use of botulinum toxin A in the dog
    Switzer, E
    Meyer-Lindenberg, A
    Wohlfarth, K
    Nolte, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R47 - R47
  • [33] Clinical relevance of botulinum toxin immunogenicity
    Benecke R.
    BioDrugs, 2012, 26 (2) : e1 - e9
  • [34] Current Clinical Applications of Botulinum Toxin
    Truong, Daniel D.
    Stenner, Andrea
    Reichel, Gerhard
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (31) : 3671 - 3680
  • [35] Clinical relevance of botulinum toxin antibodies
    Dressler, D.
    NERVENARZT, 2008, 79 : 36 - 40
  • [36] Current Australian clinical practice in use of botulinum toxin-A to manage paediatric hypertonicity
    O'Flaherty, Stephen J.
    Stewart, Kirsty
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2021, 57 (10) : 1662 - 1665
  • [37] COST ANALYSIS OF BOTULINUM TOXIN A (BOTOX® AND XEOMIN®) IN REAL-WORLD CLINICAL PRACTICE
    de Andres-Nogales, F.
    Oyaguez, I
    Morell, A.
    Casado, M. A.
    VALUE IN HEALTH, 2018, 21 : S334 - S334
  • [38] Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F
    Roberto Eleopra
    Valeria Tugnoli
    Rocco Quatrale
    Ornella Rossetto
    Cesare Montecucco
    Dirk Dressler
    Neurotoxicity Research, 2006, 9 : 127 - 131
  • [39] Repeat botulinum toxin A injections: a step forward in the challenge to evaluate current clinical practice
    Russo, Remo
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2015, 57 (08): : 702 - 703
  • [40] Clinical Practice: evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin
    Contarino, Maria Fiorella
    Van den Dool, Joost
    Balash, Yacov
    Bhatia, Kailash
    Giladi, Nir
    Koelman, Johannes H.
    Lokkegaard, Annemette
    Marti, Maria J.
    Postma, Miranda
    Relja, Maja
    Skorvanek, Matej
    Speelman, Johannes D.
    Zoons, Evelien
    Ferreira, Joaquim J.
    Vidailhet, Marie
    Albanese, Alberto
    Tijssen, Marina A. J.
    FRONTIERS IN NEUROLOGY, 2017, 8